Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal

CARLSBAD, Calif. , May 12, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 .     A live webcast and additional information about this presentation can be

On track to achieve 2022 financial guidance Webcast today, May 4, 2022 , at 11:30 a.m. Eastern Time CARLSBAD, Calif. , May 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements.

CARLSBAD, Calif. , May 2, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022 .     The agenda for the event is as follows: –

Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 20, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4 th at 11:30 a.m. Eastern Time to discuss its first quarter financial